According to US BioDesign president and founder Tom Molz, the company's relocation supports essential, short-term business goals and is key to advancing longer-term growth strategies. "This is an exciting time for US BioDesign," he says. "With multiple developmental projects nearing commercialization, this is the right time for us to expand. Our business is growing rapidly and we've got a lot of momentum moving forward. We're excited about the future."
Comprised of surgical, cardiovascular, neurovascular, neurological, orthopedic, general medical and other devices, the global medical device industry has experienced significant growth over the last five years and is expected to continue. Neurology devices are predicted to post the fastest growth, expected to expand by 6.1% per year.
"Our decision to relocate was made in response to listening to our customers and our evaluation of where we see the industry moving, based on current and emerging industry trends. This move gives us the technological bandwidth and expanded manufacturing capabilities and capacity that we need to respond with agility and flexibility as the needs of our customers evolve," says Molz.
Molz has driven discovery and innovation within the medical/biomedical textiles and implantable fabrics for medical devices industry for more than 20 years, and has been involved with biomedical textile developments in virtually all areas of the medical device industry. US BioDesign is the second biomedical manufacturing company founded by Molz.
US BioDesign is a global leader in the development and manufacture of biomedical textile structure components for medical devices across the cardiovascular, neurological and general surgery medical device segments of the health care industry. US BioDesign draws upon deep biomedical engineering expertise and an unparalleled understanding of medical device construct development involving polymeric and/or metallic raw materials to deliver elegant and efficient engineering solutions and commercial development support.